Skip to content
Markets
This is research, not advice. We’re not SEBI-registered.

API and CDMO Pharma Stocks and Companies in India

🤑🚀 Only Gland Pharma has both tags · 18 of 24 beat the NIFTY 500 over 3 years, or since listing for a newer company

🤑🚀 and 🤑 first, then by market cap🤑 Deep value (our tag): share price grew slower than profit and sales over 3 to 5 years, returns not falling🚀 Speeding up: profit and sales growth and the price all quickeningHover a company for the numbers; click a 🤑 or 🚀 bar to see it on the linesRank = our Deep value score: business 50 + speed-up 30 + lag 20
Share price, pharmas index and NIFTY 5001Y to 10Y

Acutaas Chemicals leads at +642%; 9 of the 10 shown beat the NIFTY 500

🤑🚀

Since 17 Nov 2023+165% pharmas indexMedian company +146% · NIFTY 500 +34.8%
Median company +146%
1Neuland Laboratories+291%
2Gland Pharma+105%
3Acutaas Chemicals+642%
4Granules India+118%
5OneSource Specialty Pharma−5.8%
6Sai Life Sciences+174%
7Divis Laboratories+218%
8Laurus Labs+555%
9Anthem Biosciences+23.7%
10Piramal Pharma+109%
Median company +146%
1Neuland Laboratories+291%
2Gland Pharma+105%
3Acutaas Chemicals+642%
4Granules India+118%
5OneSource Specialty Pharma−5.8%
6Sai Life Sciences+174%
7Divis Laboratories+218%
8Laurus Labs+555%
9Anthem Biosciences+23.7%
10Piramal Pharma+109%
Pharmas index, all 24 companies at equal weight: 1Y change, then growth a year1Y+41.1%3Y+38.5%/yr5Y+20.0%/yr10YToo short
Pharmas index (equal weight)NIFTY 500Companies: colours as the chips aboveRanked by our score; bars show each company's price change, a later listing from its first close; dashed line: the median company

EPS growth, TTM1Y to 10Y

Acutaas Chemicals leads at +97.6% a year over 3 years; 7 of 7 grew

🤑🚀

TTM, mostly to Sep 2026+20.9% a year, median EPS growth over 3 years10 companies, latest each
Last 12 monthsMedian +20.9%/yr
1Neuland Laboratories+19.4%/yr+88.4%
2Gland Pharma+20.9%/yr+56.3%
3Acutaas Chemicals+97.6%/yr+96.1%
4Granules India+20.2%/yr+33.6%
5OneSource Specialty Pharman/a−104%
6Sai Life Sciencesn/a+29.3%
7Divis Laboratories+36.2%/yr+35.3%
8Laurus Labs+53.7%/yr+95.7%
9Anthem Biosciences+16.5%/yr+18.5%
10Piramal Pharman/a−415%
Last 12 monthsMedian +20.9%/yr
1Neuland Laboratories+19.4%/yr+88.4%
2Gland Pharma+20.9%/yr+56.3%
3Acutaas Chemicals+97.6%/yr+96.1%
4Granules India+20.2%/yr+33.6%
5OneSource Specialty Pharman/a−104%
6Sai Life Sciencesn/a+29.3%
7Divis Laboratories+36.2%/yr+35.3%
8Laurus Labs+53.7%/yr+95.7%
9Anthem Biosciences+16.5%/yr+18.5%
10Piramal Pharman/a−415%
MedianNow, Sep 26+35.3%Sep 25+14.0%Sep 23−43.8%Mar 21+96.6%
Median of pickedLines: 3-quarter average (headline and bars: latest actual)Dotted: no figure that dateBars: latest TTM growth, ranked by our score. Right column: growth a year (3Y and longer)

Revenue growth, TTM1Y to 10Y

OneSource Specialty Pharma leads at +231.6% a year over 3 years; 10 of 10 grew

🤑🚀

TTM, mostly to Sep 2026+18.2% a year, median revenue growth over 3 years10 companies, latest each
Last 12 monthsMedian +18.2%/yr
1Neuland Laboratories+16.6%/yr+50.6%
2Gland Pharma+18.0%/yr+21.9%
3Acutaas Chemicals+33.8%/yr+45.3%
4Granules India+9.3%/yr+21.8%
5OneSource Specialty Pharma+232%/yr+10.6%
6Sai Life Sciences+21.6%/yr+15.5%
7Divis Laboratories+18.4%/yr+21.6%
8Laurus Labs+13.6%/yr+23.0%
9Anthem Biosciences+26.1%/yr−1.2%
10Piramal Pharma+9.0%/yr+9.4%
Last 12 monthsMedian +18.2%/yr(on the zero line)
1Neuland Laboratories+16.6%/yr+50.6%
2Gland Pharma+18.0%/yr+21.9%
3Acutaas Chemicals+33.8%/yr+45.3%
4Granules India+9.3%/yr+21.8%
5OneSource Specialty Pharma+232%/yr+10.6%
6Sai Life Sciences+21.6%/yr+15.5%
7Divis Laboratories+18.4%/yr+21.6%
8Laurus Labs+13.6%/yr+23.0%
9Anthem Biosciences+26.1%/yr−1.2%
10Piramal Pharma+9.0%/yr+9.4%
MedianNow, Sep 26+21.7%Sep 25+19.3%Sep 23+6.3%Mar 21+30.4%
Median of pickedLines: 3-quarter average (headline and bars: latest actual)Dotted: no figure that dateBars: latest TTM growth, ranked by our score. Right column: growth a year (3Y and longer)

ROCE, TTM1Y to 10Y

Acutaas Chemicals leads at 36.7%; lowest OneSource Specialty Pharma 1.4%

🤑🚀

TTM, mostly to Sep 202621.3% median ROCE10 companies, latest each
Median 21.3%
1Neuland Laboratories29.9%
2Gland Pharma16.9%
3Acutaas Chemicals36.7%
4Granules India15.6%
5OneSource Specialty Pharma1.4%
6Sai Life Sciences18.0%
7Divis Laboratories26.6%
8Laurus Labs24.5%
9Anthem Biosciences27.7%
10Piramal Pharma2.8%
Median 21.3%
1Neuland Laboratories29.9%
2Gland Pharma16.9%
3Acutaas Chemicals36.7%
4Granules India15.6%
5OneSource Specialty Pharma1.4%
6Sai Life Sciences18.0%
7Divis Laboratories26.6%
8Laurus Labs24.5%
9Anthem Biosciences27.7%
10Piramal Pharma2.8%
MedianNow, Sep 2621.3%Mar 2514.8%Mar 2319.4%Mar 2130.0%
Median of pickedLines: yearly figuresDotted: no figure that dateBars: latest TTM figure, ranked by our score

🤑 Deep value (our tag): share price grew slower than profit and sales over 3 to 5 years, returns not falling

🚀 Speeding up: profit and sales growth and the price all quickening

Rank = our Deep value score: business 50 + speed-up 30 + lag 20

Industry · 24 companies

There are 24 listed API and CDMO Pharma stocks in India. The largest by market value are Divi's Lab (₹2.93 lakh crore), Laurus Labs (₹1.25 lakh crore), Gland Pharma (₹53,306 crore), Anthem Biosciences and Sai Life Sciences, at prices of 18 November 2026. 13 of the 24 companies we track are beating the Nifty 500 on share price over recent months.

API and CDMO Pharma: Divis Laboratories Ltd owns the largest revenue base; Neuland Laboratories Ltd has the fastest current growth.

The main question: the biggest companies are not always the ones changing the most.

Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.

Our full read on API and CDMO Pharma companies, including what their managements promised and what could stop the run, is in the Sector Alpha newsletter.

How big is the API and CDMO Pharma sector?

There are 24 listed API and CDMO Pharma companies on this page, worth ₹8.1 lakh cr together at prices of 18 November 2026. Divi's Lab alone is ₹2.9 lakh cr, about 36% of the total.

24Companies every listed company in this industry
₹8.1 lakh crCombined market value all of them together
19/24Revenue growing revenue over the last 12 months up on a year earlier
13/24Beating NIFTY 500 pass the weekly momentum test: 5+ points ahead over 3 months, within 20% of the 52-week high
13 of 24 pass the weekly momentum test (5+ points ahead of the NIFTY 500 over 3 months, within 20% of the 52-week high)

Market values at prices of 18 November 2026.

What did API and CDMO Pharma managements say about July to September 2026?

13 of 13 Pharma - API & CRAMS companies held a results call for July to September 2026. Dishman Carbogen Amcis guided: FY27 no revenue growth expected as deferred orders shift to next year.

Dishman Carbogen Amcis call 16 November 2026

“Our consideration is if AI development continues slowing down, some shift of venture capital into some medical industry is expected.”Stephan Fritschi

Guided: FY27 no revenue growth expected as deferred orders shift to next year.

Innova Captab call 16 November 2026

“Abhi, if you see that the business model with 3 times the FATR and 15-16% EBITDA will also result in 16-17% ROE with 90 days of working capital, it is simple mathematics.”Management

Guided: Volume growth 20% in coming years with 2-year runway on existing assets and ₹400 crore treasury for greenfield or inorganic beyond FY29.

Divis Laboratories call 7 November 2026

“All I will say is that, with our futuristic capacity, we will be among the top three players.”Kiran S. Divi

Guided: FY27 revenue growth double-digit reiterated as forward path without pinning H2 pace.

Sai Life Sciences call 6 November 2026

“We believe that such integrated partnerships will help us build a robust, consistent, and predictable long-term pipeline and revenue base.”Krishna Kanumuri

Guided: H2 FY27 performance stronger than H1.

Windlas Biotech call 6 November 2026

“My instinct is to say that this is credit to the team rather than credit to API prices.”Hitesh Windlass

Guided: Company-level base can serve up to about ₹1,100 crore plus around 10% debottlenecking headroom.

Blue Jet Healthcare call 5 November 2026

“Our ambition is not simply to add manufacturing capacity. We are building a globally competitive CDMO platform that combines decades of complex chemistry expertise with integrated R&D, flexible manufacturing infrastructure, and long-standing relationships with global pharmaceutical innovators.”Shiven Arora

Guided: Mahad Unit 3 KSM backward-integration facility planned on stream in H2FY27, enabling full chain integration.

Anthem Biosciences call 4 November 2026

“We have further solidified our industry-leading margins and are well-positioned to sustain this performance for the whole year.”Ajay Bharadwaj

Guided: Double-digit revenue growth try for FY27 to offset slow Q1.

Hikal call 3 November 2026

“It is a pure CDMO niche molecule, and the EBITDA will be well in excess of the EBITDA margins of the company.”Sameer Hiremath

Guided: FY27 mid-teen revenue growth reiterated with H2 topline significantly stronger than H1.

5 more Pharma - API & CRAMS calls held for July to September 2026 are not shown here, to keep the page fast.

From the results calls for July to September 2026.

Is money moving into API and CDMO Pharma stocks? Who is adding capacity?

Big funds, foreign and Indian, raised their stake by 0.4 points over the last two quarters. Founders and promoters kept theirs about the same.

  • Spending on new plants and equipment was ₹12,660 crore in the last 12 months, 27% more than a year before.
  • Projects still being built grew 23% in a year.
  • 2 Pharma - API & CRAMS calls in the last quarters talked about adding capacity.

Big funds = foreign and Indian institutions, change in their share of ownership across 26 Pharma - API & CRAMS companies, in percentage points.

Ownership and spending as of 10 October 2026.

What to watch next in API and CDMO Pharma stocks?

The next things that show whether the Pharma - API & CRAMS story is on course. First: Anthem's expected recovery in deliveries and plant use after its soft first quarter.

  • Gland's constrained vial-line approval and contract conversion.
  • Neuland's peptide commissioning and qualification after the revised schedule.
  • Acutaas's commercial contribution from validated manufacturing products.
  • Granules's expected peptide-business profitability in FY27.
  • Shilpa's partner resubmission and clarification of delayed launch dates.

What would change the story

A next reported quarter in which combined profit falls below the same quarter a year earlier while operating margin also falls below that quarter's level would break the earnings-supported breakout call.

From our industry review of 10 October 2026.

Which are the biggest API and CDMO Pharma stocks in India?

The largest API and CDMO Pharma stocks in India by market value are Divi's Lab (₹2.93 lakh crore), Laurus Labs (₹1.25 lakh crore) and Gland Pharma (₹53,306 crore), at prices of 18 Nov 2026.

The other 14 API and CDMO Pharma companies are in the full list below.

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 18 Nov 2026; the score list below uses the weekly figures.

Which are the API and CDMO Pharma stocks, ranked?

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). The scores come from our weekly scan.

  1. 1Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr74.4of 100favourable · strongest on relative strength versus sector and ROCE improvement
  2. 2Acutaas Chemicals LtdACUTAAS · ₹32,700 cr74.1of 100favourable · strongest on ROCE and ROCE improvement
  3. 3Divis Laboratories LtdDIVISLAB · ₹2.9 lakh cr68.7of 100favourable · strongest on ROCE and margin improvement
  4. 4Gland Pharma LtdGLAND · ₹53,300 cr67.7of 100favourable · strongest on ROCE improvement and relative strength versus sector
  5. 5IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr65.2of 100favourable · strongest on relative strength versus sector and ROCE improvement
  6. 6Neuland Laboratories LtdNEULANDLAB · ₹27,500 cr65.0of 100favourable · strongest on ROCE and ROCE improvement
  7. 7Shilpa Medicare LtdSHILPAMED · ₹17,900 cr64.1of 100mixed, leaning good · strongest on profit growth and relative strength versus sector
  8. 8Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr63.4of 100mixed, leaning good · strongest on ROCE improvement and profit growth
  9. 9Sai Life Sciences LtdSAILIFE · ₹38,000 cr58.3of 100mixed, leaning good · strongest on relative strength versus sector and ROCE
  10. 10SMS Pharmaceuticals LtdSMSPHARMA · ₹4,470 cr56.0of 100mixed, leaning good · strongest on 13-week relative-strength change and profit growth

Is there a Nifty API and CDMO Pharma index, and what is in it?

The largest 15 of 24 listed Indian Pharma - API & CRAMS companies are named here; all 24 are ranked in the scorecard. This is the set of companies people mean when they search for a Nifty Pharma - API & CRAMS index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one.

  1. Divis Laboratories Ltd₹2.9 lakh cr
  2. Laurus Labs Ltd₹1.3 lakh cr
  3. Gland Pharma Ltd₹53,300 cr
  4. Anthem Biosciences Ltd₹51,500 cr
  5. Sai Life Sciences Ltd₹38,000 cr
  6. Acutaas Chemicals Ltd₹32,700 cr
  7. Piramal Pharma Ltd₹31,700 cr
  8. Neuland Laboratories Ltd₹27,500 cr
  9. Granules India Ltd₹21,800 cr
  10. Shilpa Medicare Ltd₹17,900 cr
  11. OneSource Specialty Pharma Ltd₹18,200 cr
  12. Syngene International Ltd₹17,600 cr
  13. Cohance Lifesciences Ltd₹17,500 cr
  14. Jubilant Pharmova Ltd₹14,900 cr
  15. Concord Biotech Ltd₹11,700 cr

The remaining 9 Pharma - API & CRAMS companies are named and ranked in the scorecard.

How many API and CDMO Pharma companies are listed in India?

24 API and CDMO Pharma companies in the Pharma - API & CRAMS industry group have a page on Sector Alpha, and all 24 are listed below, largest first. The largest is Divis Laboratories (₹2.93 lakh crore) and the smallest with a market value is Dishman Carbogen Amcis.

Every Pharma - API & CRAMS company with a page, largest first
CompanyMarket value
1. Divis Laboratories Ltd DIVISLAB₹2.93 lakh crore
2. Laurus Labs Ltd LAURUSLABS₹1.25 lakh crore
3. Gland Pharma Ltd GLAND₹53,306 crore
4. Anthem Biosciences Ltd ANTHEM₹51,522 crore
5. Sai Life Sciences Ltd SAILIFE₹38,012 crore
6. Acutaas Chemicals Ltd ACUTAAS₹32,678 crore
7. Piramal Pharma Ltd PPLPHARMA₹31,744 crore
8. Neuland Laboratories Ltd NEULANDLAB₹27,527 crore
9. Granules India Ltd GRANULES₹21,754 crore
10. OneSource Specialty Pharma Ltd ONESOURCE₹18,190 crore
11. Shilpa Medicare Ltd SHILPAMED₹17,902 crore
12. Syngene International Ltd SYNGENE₹17,552 crore
13. Cohance Lifesciences Ltd COHANCE₹17,463 crore
14. Jubilant Pharmova Ltd JUBLPHARMA₹14,872 crore
15. Concord Biotech Ltd CONCORDBIO₹11,738 crore
16. Blue Jet Healthcare Ltd BLUEJET₹9,814 crore
17. IOL Chemicals & Pharmaceuticals Ltd IOLCP₹5,569 crore
18. Morepen Laboratories Ltd MOREPENLAB₹5,062 crore
19. Supriya Lifescience Ltd SUPRIYA₹4,948 crore
20. SMS Pharmaceuticals Ltd SMSPHARMA₹4,465 crore
21. Solara Active Pharma Sciences Ltd SOLARA₹3,157 crore
22. Hikal Ltd HIKAL₹2,751 crore
23. Windlas Biotech Ltd WINDLAS₹2,041 crore
24. Dishman Carbogen Amcis Ltd DCAL₹1,899 crore

Download all 24 API and CDMO Pharma companies (CSV)

How have API and CDMO Pharma stocks moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 36% ahead of NIFTY 500. Earnings across its companies grew 17% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 34 weeks running.

Leader · ahead 34w ~

Price and the fundamentals both up. 13 of 24 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).

Ahead of NIFTY 500 on the three-month view for 34 weeks running; 21 of the 24 companies in the industry index above their 200-day average (1 more than four weeks earlier); 13 of those 24 pass the momentum test (no change from four weeks earlier); earnings rising at 13 of the 24 that report earnings.

Ahead of NIFTY 500 for 34 weeks running and +39.4% over a year, with 13 → 13 of 24 stocks participating. Earnings mixed, 13 of 24 members have higher trailing twelve-month earnings than a year ago.

1Y

Pharma - API & CRAMS against NIFTY 500

Both lines start at 200 in the first week shown

  • API and CDMO Pharma 288
  • NIFTY 500 200
Pharma - API & CRAMS against NIFTY 500
Week endingAPI and CDMO PharmaNIFTY 500
21 Nov 2025200200
28 Nov 2025203201
5 Dec 2025200200
12 Dec 2025200199
19 Dec 2025200199
26 Dec 2025200200
2 Jan 2026202203
9 Jan 2026196197
16 Jan 2026193197
23 Jan 2026178191
30 Jan 2026178194
6 Feb 2026179197
13 Feb 2026182196
20 Feb 2026181197
27 Feb 2026184195
6 Mar 2026179189
13 Mar 2026174180
20 Mar 2026176179
27 Mar 2026178177
3 Apr 2026177176
10 Apr 2026190188
17 Apr 2026196192
24 Apr 2026195190
1 May 2026205191
8 May 2026217194
15 May 2026214189
22 May 2026221190
29 May 2026223190
5 Jun 2026226189
12 Jun 2026230190
19 Jun 2026228195
26 Jun 2026232194
3 Jul 2026244196
10 Jul 2026245196
17 Jul 2026243196
24 Jul 2026236193
31 Jul 2026242197
7 Aug 2026256199
14 Aug 2026257198
21 Aug 2026262198
28 Aug 2026267198
4 Sep 2026272195
11 Sep 2026280192
18 Sep 2026281192
25 Sep 2026281190
2 Oct 2026273184
9 Oct 2026266184
16 Oct 2026266187
23 Oct 2026252180
30 Oct 2026275184
6 Nov 2026282197
13 Nov 2026288200

3Y

Pharma - API & CRAMS against NIFTY 500

Both lines start at 200 in the first week shown, every 2nd week shown

  • API and CDMO Pharma 516
  • NIFTY 500 269
Pharma - API & CRAMS against NIFTY 500
Week endingAPI and CDMO PharmaNIFTY 500
24 Nov 2023200200
1 Dec 2023202205
15 Dec 2023203217
29 Dec 2023212220
12 Jan 2024219224
26 Jan 2024211220
9 Feb 2024220226
23 Feb 2024229230
8 Mar 2024226232
22 Mar 2024221227
5 Apr 2024237235
19 Apr 2024240231
3 May 2024244238
17 May 2024238239
31 May 2024233239
14 Jun 2024252252
28 Jun 2024260256
12 Jul 2024273262
26 Jul 2024281264
9 Aug 2024298260
23 Aug 2024315265
6 Sep 2024338266
20 Sep 2024354274
4 Oct 2024340267
18 Oct 2024350266
1 Nov 2024361259
15 Nov 2024359249
29 Nov 2024383257
13 Dec 2024374265
27 Dec 2024368254
10 Jan 2025358247
24 Jan 2025344242
7 Feb 2025362245
21 Feb 2025326235
7 Mar 2025333232
21 Mar 2025346241
4 Apr 2025331236
18 Apr 2025344246
2 May 2025332249
16 May 2025343259
30 May 2025366258
13 Jun 2025373260
27 Jun 2025371268
11 Jul 2025373264
25 Jul 2025381261
8 Aug 2025361254
22 Aug 2025376261
5 Sep 2025378259
19 Sep 2025394266
3 Oct 2025376261
17 Oct 2025381268
31 Oct 2025382269
14 Nov 2025372270
28 Nov 2025362271
12 Dec 2025359269
26 Dec 2025357270
9 Jan 2026351266
23 Jan 2026319257
6 Feb 2026321266
20 Feb 2026324265
6 Mar 2026321255
20 Mar 2026315242
3 Apr 2026316237
17 Apr 2026351259
1 May 2026367257
15 May 2026383255
29 May 2026399257
12 Jun 2026411256
26 Jun 2026415262
10 Jul 2026438265
24 Jul 2026422260
7 Aug 2026459269
21 Aug 2026469267
4 Sep 2026486264
18 Sep 2026502259
2 Oct 2026489248
16 Oct 2026476252
30 Oct 2026493248
13 Nov 2026516269

5Y

Pharma - API & CRAMS against NIFTY 500

Both lines start at 200 in the first week shown, every 4th week shown

  • API and CDMO Pharma 505
  • NIFTY 500 323
Pharma - API & CRAMS against NIFTY 500
Week endingAPI and CDMO PharmaNIFTY 500
26 Nov 2021200200
17 Dec 2021194200
14 Jan 2022207214
11 Feb 2022180203
11 Mar 2022175194
8 Apr 2022192209
6 May 2022172192
3 Jun 2022155191
1 Jul 2022148182
29 Jul 2022156199
26 Aug 2022158206
23 Sep 2022155205
21 Oct 2022151205
18 Nov 2022150211
16 Dec 2022149213
13 Jan 2023148209
10 Feb 2023134204
10 Mar 2023135200
7 Apr 2023136201
5 May 2023146208
2 Jun 2023154215
30 Jun 2023164223
28 Jul 2023173230
25 Aug 2023184229
22 Sep 2023187235
20 Oct 2023183234
17 Nov 2023191239
15 Dec 2023198260
12 Jan 2024214269
9 Feb 2024215271
8 Mar 2024221278
5 Apr 2024232282
3 May 2024238285
31 May 2024228287
28 Jun 2024255307
26 Jul 2024275317
23 Aug 2024308318
20 Sep 2024346329
18 Oct 2024343319
15 Nov 2024351299
13 Dec 2024366318
10 Jan 2025350296
7 Feb 2025354294
7 Mar 2025326278
4 Apr 2025324283
2 May 2025324299
30 May 2025358310
27 Jun 2025363321
25 Jul 2025372313
22 Aug 2025368313
19 Sep 2025386319
17 Oct 2025372321
14 Nov 2025363324
12 Dec 2025351323
9 Jan 2026344319
6 Feb 2026314319
6 Mar 2026314306
3 Apr 2026309285
1 May 2026359308
29 May 2026391308
26 Jun 2026406314
24 Jul 2026412312
21 Aug 2026458320
18 Sep 2026491311
16 Oct 2026466303
13 Nov 2026505323

Earnings, each company rebased to 100, the sector takes the median

Latest quarter July to September 2026: 144.6, from 21 companies

Earnings, each company rebased to 100, the sector takes the median
QuarterMedian earnings index
Apr 2022100.0 (13 companies)
Jul 202288.9 (15 companies)
Oct 202276.9 (15 companies)
Jan 202371.5 (15 companies)
Apr 202368.3 (17 companies)
Jul 202383.3 (19 companies)
Oct 202385.9 (19 companies)
Jan 202477.3 (19 companies)
Apr 202477.2 (19 companies)
Jul 202494.4 (20 companies)
Oct 2024103.5 (20 companies)
Jan 2025112.8 (21 companies)
Apr 2025102.9 (21 companies)
Jul 2025108.2 (21 companies)
Oct 2025107.1 (21 companies)
Jan 2026119.3 (21 companies)
Apr 2026127.0 (21 companies)
Jul 2026144.6 (21 companies)

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 24 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Are API and CDMO Pharma stocks outperforming NIFTY 500?

Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over the last 52 weeks. Over 13 weeks the gap is a lead of 11.8%. Shilpa Medicare Ltd is the strongest against the sector itself at +43.4%. Readings are as of 13 November 2026.

+11.8%Sector vs NIFTY 500 · 13 weeks
+34.7%Sector vs NIFTY 500 · 52 weeks
13 of 24Stocks leading NIFTY 500
8 of 24Stocks leading the sector

Relative-strength score for the industry: 19.2 as of 13 November 2026 (leaders, rising).

What is the bottom line on API and CDMO Pharma stocks?

Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over 52 weeks and by 11.8% over 13 weeks. 13 of 24 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 8 of the 18 with a long enough price history are ahead of the industry itself.

How does each API and CDMO Pharma stock score?

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Growth & earnings · 35% Capital efficiency · 25% Valuation · 20% Relative strength · 20%

Laurus Labs Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 93% evidence confidence.

Blue Jet Healthcare Ltd scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

  1. 1Laurus Labs LtdLAURUSLABS · leader · favourable · 93% evidence74.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 32.2/35 · Revenue 23% · PAT 95.3% · OPM change 10 pp · 100% evidenceCapital efficiency 17.4/25 · ROCE 17.8% (year to Mar 2026) · OPM 34% · 100% evidenceValuation 7.1/20 · P/E 93.7× · PEG 2.27 · 65% evidenceRelative strength 17.7/20 · RS sector 35.5% · RS bench 63.4% · 1Y 137.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 32.2 + 17.4 + 7.1 + 17.7 = 74.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Acutaas Chemicals LtdACUTAAS · turning · favourable · 67% evidence74.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 32.0/35 · Revenue 45.4% · PAT 95.5% · OPM change 9 pp · 95% evidenceCapital efficiency 20.2/25 · ROCE 31.6% (year to Mar 2026) · OPM 40.3% · 76% evidenceValuation 10.4/20 · P/E 74.4× · PEG — · 50% evidenceRelative strength 11.5/20 · RS sector — · RS bench 43.7% · 1Y 134.5% · 25% evidence · 3 of 9 weeks aheadExact sum: 32 + 20.2 + 10.4 + 11.5 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  3. 3Divis Laboratories LtdDIVISLAB · leader · favourable · 100% evidence68.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.6/35 · Revenue 21.6% · PAT 35.3% · OPM change 10 pp · 100% evidenceCapital efficiency 19.6/25 · ROCE 22% (year to Mar 2026) · OPM 42.6% · 100% evidenceValuation 3.0/20 · P/E 87.2× · PEG 2.88 · 100% evidenceRelative strength 17.5/20 · RS sector 22.7% · RS bench 50.5% · 1Y 73.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.6 + 19.6 + 3 + 17.5 = 68.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  4. 4Gland Pharma LtdGLAND · leader · favourable · 100% evidence67.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.1/35 · Revenue 21.9% · PAT 56.3% · OPM change 5 pp · 100% evidenceCapital efficiency 17.1/25 · ROCE 15.1% (year to Mar 2026) · OPM 26.4% · 100% evidenceValuation 10.2/20 · P/E 43.1× · PEG 1.84 · 100% evidenceRelative strength 12.3/20 · RS sector 18.8% · RS bench 44.6% · 1Y 78.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.1 + 17.1 + 10.2 + 12.3 = 67.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  5. 5IOL Chemicals & Pharmaceuticals LtdIOLCP · leader · favourable · 90% evidence65.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 29.2/35 · Revenue 26.7% · PAT 75% · OPM change 4 pp · 100% evidenceCapital efficiency 12.7/25 · ROCE 11.3% (year to Mar 2026) · OPM 13.7% · 100% evidenceValuation 9.3/20 · P/E 27.4× · PEG — · 50% evidenceRelative strength 14.0/20 · RS sector 30.8% · RS bench 55.8% · 1Y 110.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 29.2 + 12.7 + 9.3 + 14 = 65.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Neuland Laboratories LtdNEULANDLAB · fading · favourable · 100% evidence65.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.7/35 · Revenue 50.5% · PAT 88.4% · OPM change −8 pp · 100% evidenceCapital efficiency 21.9/25 · ROCE 26.5% (year to Mar 2026) · OPM 21.8% · 100% evidenceValuation 10.0/20 · P/E 60.8× · PEG 1.91 · 100% evidenceRelative strength 6.4/20 · RS sector −3.9% · RS bench 17.8% · 1Y 29.3% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.7 + 21.9 + 10 + 6.4 = 65 · What this means: Earnings are strong; relative strength in its sector is −3.9% and the one-year return is 29.3%.
  7. 7Shilpa Medicare LtdSHILPAMED · leader · mixed, leaning good · 93% evidence64.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.6/35 · Revenue 37.4% · PAT 100% · OPM change −2 pp · 100% evidenceCapital efficiency 12.2/25 · ROCE 10.9% (year to Mar 2026) · OPM 26.8% · 100% evidenceValuation 12.6/20 · P/E 53.8× · PEG 1.42 · 65% evidenceRelative strength 14.7/20 · RS sector 43.4% · RS bench 69% · 1Y 161.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.6 + 12.2 + 12.6 + 14.7 = 64.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Morepen Laboratories LtdMOREPENLAB · leader · mixed, leaning good · 75% evidence63.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 31.8/35 · Revenue 30.1% · PAT 90.9% · OPM change 9 pp · 100% evidenceCapital efficiency 9.3/25 · ROCE 8.1% (year to Mar 2026) · OPM 16.5% · 100% evidenceValuation 10.4/20 · P/E 26.9× · PEG — · 50% evidenceRelative strength 11.9/20 · RS sector — · RS bench 52.4% · 1Y 109.9% · 25% evidence · 12 of 12 weeks aheadExact sum: 31.8 + 9.3 + 10.4 + 11.9 = 63.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Sai Life Sciences LtdSAILIFE · leader · mixed, leaning good · 93% evidence58.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.2/35 · Revenue 15.5% · PAT 31.1% · OPM change 1 pp · 100% evidenceCapital efficiency 15.8/25 · ROCE 19.6% (year to Mar 2026) · OPM 28.2% · 100% evidenceValuation 4.5/20 · P/E 100.7× · PEG 3.55 · 65% evidenceRelative strength 17.8/20 · RS sector 29.5% · RS bench 57.9% · 1Y 107.6% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.2 + 15.8 + 4.5 + 17.8 = 58.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10SMS Pharmaceuticals LtdSMSPHARMA · breaking out · mixed, leaning good · 90% evidence56.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.5/35 · Revenue 13% · PAT 41% · OPM change 1 pp · 100% evidenceCapital efficiency 11.9/25 · ROCE 13.3% (year to Mar 2026) · OPM 21.5% · 100% evidenceValuation 8.3/20 · P/E 38.2× · PEG — · 50% evidenceRelative strength 15.3/20 · RS sector 2.4% · RS bench 27.1% · 1Y 69.1% · 100% evidence · 10 of 12 weeks aheadExact sum: 20.5 + 11.9 + 8.3 + 15.3 = 56 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Anthem Biosciences LtdANTHEM · fading · mixed, leaning good · 93% evidence53.0out of 100GrowthCapitalValuationRelative
  12. 12Windlas Biotech LtdWINDLAS · fading · mixed, leaning good · 75% evidence52.6out of 100GrowthCapitalValuationRelative
  13. 13Granules India LtdGRANULES · quiet · mixed, leaning good · 100% evidence51.8out of 100GrowthCapitalValuationRelative
  14. 14Solara Active Pharma Sciences LtdSOLARA · leader · mixed, leaning good · 74% evidence50.2out of 100GrowthCapitalValuationRelative
  15. 15Blue Jet Healthcare LtdBLUEJET · quiet · mixed, leaning weak · 85% evidence48.9out of 100GrowthCapitalValuationRelative
  16. 16Concord Biotech LtdCONCORDBIO · quiet · mixed, leaning weak · 85% evidence46.1out of 100GrowthCapitalValuationRelative
  17. 17Piramal Pharma LtdPPLPHARMA · leader · mixed, leaning weak · 71% evidence44.0out of 100GrowthCapitalValuationRelative
  18. 18Hikal LtdHIKAL · turning · mixed, leaning weak · 78% evidence40.1out of 100GrowthCapitalValuationRelative
  19. 19Supriya Lifescience LtdSUPRIYA · quiet · mixed, leaning weak · 100% evidence39.1out of 100GrowthCapitalValuationRelative
  20. 20OneSource Specialty Pharma LtdONESOURCE · turning · weak · 80% evidence30.9out of 100GrowthCapitalValuationRelative
  21. 21Jubilant Pharmova LtdJUBLPHARMA · turning · weak · 90% evidence30.8out of 100GrowthCapitalValuationRelative
  22. 22Cohance Lifesciences LtdCOHANCE · fading · weak · 82% evidence24.9out of 100GrowthCapitalValuationRelative
  23. 23Dishman Carbogen Amcis LtdDCAL · basing · weak · 68% evidence24.8out of 100GrowthCapitalValuationRelative
  24. 24Syngene International LtdSYNGENE · turning · weak · 100% evidence24.5out of 100GrowthCapitalValuationRelative
How this score is built, and what the marks mean

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

How have API and CDMO Pharma share prices moved?

Shilpa Medicare Ltd has the strongest one-year price move in Pharma - API & CRAMS at +161.1%. It also leads on relative strength against the NIFTY, at +69.0%. 18 of 24 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Pharma - API & CRAMS itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

  1. 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+161.1%1 year
  2. 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+137.4%1 year
  3. 3Acutaas Chemicals LtdACUTAAS · ₹32,700 cr+134.5%1 year
  4. 4IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+110.1%1 year
  5. 5Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr+109.9%1 year

Strongest against NIFTY 500

  1. 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+69.0%vs NIFTY 500
  2. 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+63.4%vs NIFTY 500
  3. 3Sai Life Sciences LtdSAILIFE · ₹38,000 cr+57.9%vs NIFTY 500
  4. 4IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+55.8%vs NIFTY 500
  5. 5Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr+52.4%vs NIFTY 500

Strongest against the sector itself

  1. 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+43.4%vs sector
  2. 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+35.5%vs sector
  3. 3IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+30.8%vs sector
  4. 4Sai Life Sciences LtdSAILIFE · ₹38,000 cr+29.5%vs sector
  5. 5Divis Laboratories LtdDIVISLAB · ₹2.9 lakh cr+22.7%vs sector

Why are API and CDMO Pharma stocks moving?

The monthly price and earnings indices began near 84.2 and 100.2 in December 2016; by December 2019, prices were 112.5 while earnings were still 84. Prices then surged to 358.6 by September 2021, alongside earnings of 140.9, before falling to 188.7 by March 2023. In the week of 5 October 2026, 87.5% of 24 Pharma - API & CRAMS companies were beating the Nifty 500, against 52.2% on 25 May 2026.

Pharma - API & CRAMS is one of the Top 25 sectors in our latest review.

Pharma - API & CRAMS: share of companies beating the Nifty 500, and above their 200-day average, to 5 October 2026, last sector review

  • Beating the Nifty 500 87.5%
  • Above the 200-day average 66.7%
Pharma - API & CRAMS: share of companies beating the Nifty 500, and above their 200-day average, to 5 October 2026, last sector review
WeekBeating the Nifty 500Above the 200-day average
25 May 202652.2%66.7%
1 Jun 202652.2%58.3%
8 Jun 202656.5%66.7%
15 Jun 202656.5%66.7%
22 Jun 202660.9%66.7%
29 Jun 202660.9%75%
6 Jul 202665.2%70.8%
13 Jul 202675%87.5%
20 Jul 202670.8%70.8%
27 Jul 202666.7%70.8%
3 Aug 202675%75%
10 Aug 202670.8%70.8%
17 Aug 202675%70.8%
24 Aug 202675%70.8%
31 Aug 202679.2%79.2%
7 Sep 202683.3%83.3%
14 Sep 202683.3%83.3%
21 Sep 202687.5%79.2%
28 Sep 202687.5%75%
5 Oct 202687.5%66.7%

Each week, the share of Pharma - API &

From our industry review of 10 October 2026.

What is changing for API and CDMO Pharma companies?

Customer contracts and new products provide further growth, but approvals and delivery dates remain uncertain.

Pharma - API & CRAMS: what is changing, company by company
What is changingWhich companiesLasting?
Higher-value products and a better mixDivi's, Laurus, Gland, Acutaas, Granules and Shilpa describe a shift toward more differentiated work or products.looks lasting
A bigger order booklooks lasting
Costs spread over more salesLaurus, Gland, Piramal and Acutaas report benefits from higher sales or better plant use.may be cyclical
More business from existing customersSai Life describes expanding integrated customer programmes; Gland's driver read records growth from existing customers.too early to call
New productsGland has an established launch stream, Divi's has commercial contrast-media supply, and Acutaas describes additional validated products.too early to call
A bigger market to serveGland, Sai Life, Laurus and Granules are building capabilities for peptides or other complex therapies.too early to call

From our industry review of 10 October 2026.

Which API and CDMO Pharma companies have the most revenue, and which grow fastest?

Divis Laboratories Ltd has the highest Revenue among the 24 Pharma - API & CRAMS companies compared here, at ₹12,191 crore. Piramal Pharma Ltd is next at ₹9,779 crore. Neuland Laboratories Ltd has the highest Revenue growth at 50.5%, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Divis Laboratories Ltd is the largest at ₹12,191 crore, 24.7% ahead of Piramal Pharma Ltd. Neuland Laboratories Ltd's growth is 50.5% from a ₹2,308 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

Divis Laboratories Ltd · ₹12,191 croreLeader
24.7% versus #2 · Piramal Pharma LtdGap
8/8 recent comparable periodsPersistence
24/24 companies · 450 observationsCoverage

What this means: Divis Laboratories Ltd is the size to compare against; Neuland Laboratories Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Divis Laboratories Ltd's growth falls below Neuland Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

  1. 1Divis Laboratories LtdDIVISLAB₹12,200 cr
  2. 2Piramal Pharma LtdPPLPHARMA₹9,780 cr
  3. 3Jubilant Pharmova LtdJUBLPHARMA₹9,010 cr
  4. 4Laurus Labs LtdLAURUSLABS₹7,820 cr
  5. 5Gland Pharma LtdGLAND₹7,070 cr

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue, every company
CompanyRevenueRevenue growthReported
Divis Laboratories Ltd DIVISLAB₹3,680 cr35%Sep 2026
Piramal Pharma Ltd PPLPHARMA₹2,620 cr28%Sep 2026
Jubilant Pharmova Ltd JUBLPHARMA₹2,370 cr21%Sep 2026
Laurus Labs Ltd LAURUSLABS₹2,210 cr33%Sep 2026
Gland Pharma Ltd GLAND₹1,830 cr23%Sep 2026
Granules India Ltd GRANULES₹1,560 cr20%Sep 2026
Syngene International Ltd SYNGENE₹833 cr−8.6%Sep 2026
IOL Chemicals & Pharmaceuticals Ltd IOLCP₹795 cr40%Sep 2026
Morepen Laboratories Ltd MOREPENLAB₹746 cr81%Sep 2026
Sai Life Sciences Ltd SAILIFE₹659 cr23%Sep 2026
Anthem Biosciences Ltd ANTHEM₹594 cr8.0%Sep 2026
Shilpa Medicare Ltd SHILPAMED₹529 cr43%Sep 2026
OneSource Specialty Pharma Ltd ONESOURCE₹516 cr37%Sep 2026
Dishman Carbogen Amcis Ltd DCAL₹507 cr−22%Sep 2026
Cohance Lifesciences Ltd COHANCE₹477 cr−14%Sep 2026
Neuland Laboratories Ltd NEULANDLAB₹450 cr−12%Sep 2026
Acutaas Chemicals Ltd ACUTAAS₹437 cr43%Sep 2026
Hikal Ltd HIKAL₹434 cr36%Sep 2026
Solara Active Pharma Sciences Ltd SOLARA₹417 cr33%Sep 2026
Blue Jet Healthcare Ltd BLUEJET₹376 cr128%Sep 2026
SMS Pharmaceuticals Ltd SMSPHARMA₹316 cr31%Sep 2026
Concord Biotech Ltd CONCORDBIO₹309 cr25%Sep 2026
Windlas Biotech Ltd WINDLAS₹264 cr19%Sep 2026
Supriya Lifescience Ltd SUPRIYA₹206 cr3.0%Sep 2026

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

What to watch

Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.

Which API and CDMO Pharma companies keep the most from each ₹100 of sales?

Anthem Biosciences Ltd has the highest OPM among the 24 Pharma - API & CRAMS companies compared here, at 45.6%. Divis Laboratories Ltd is next at 42.6%. Divis Laboratories Ltd has the highest Margin change at +10 percentage points, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Anthem Biosciences Ltd leads opm at 45.6%; Divis Laboratories Ltd leads margin change at +10 percentage points.

Anthem Biosciences Ltd · 45.6%Leader
7% versus #2 · Divis Laboratories LtdGap
7/8 recent comparable periodsPersistence
24/24 companies · 458 observationsCoverage

What this means: Anthem Biosciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM, by reported quarter

  • Anthem Biosciences 46%
  • Divis Laboratories 43%
  • Acutaas Chemicals 40%
  • Laurus Labs 34%
  • Concord Biotech 34%
OPM, by reported quarter
QuarterAnthem BiosciencesDivis LaboratoriesAcutaas ChemicalsLaurus LabsConcord Biotech
Dec 2021—44%21%28%—
Mar 2022—44%18%28%—
Jun 2022—38%17%30%36%
Sep 2022—33%19%28%24%
Dec 2022—24%20%26%46%
Mar 2023—25%22%21%47%
Jun 202330%28%22%14%37%
Sep 202330%25%14%15%44%
Dec 202330%26%16%15%44%
Mar 202430%32%19%17%41%
Jun 202436%29%17%14%38%
Sep 202437%31%20%15%43%
Dec 202432%32%25%20%40%
Mar 202540%34%28%24%44%
Jun 202535%30%25%24%30%
Sep 202540%33%31%24%36%
Dec 202537%34%38%27%35%
Mar 202644%33%42%28%36%
Jun 202636%41%34%32%32%
Sep 202646%43%40%34%34%

Margin change, by reported quarter

  • Anthem Biosciences +6.0 pp
  • Divis Laboratories +10.0 pp
  • Acutaas Chemicals +9.0 pp
  • Laurus Labs +10.0 pp
  • Concord Biotech −2.0 pp
Margin change, by reported quarter
QuarterAnthem BiosciencesDivis LaboratoriesAcutaas ChemicalsLaurus LabsConcord Biotech
Dec 2021—+3.4 pp−2.4 pp−5.4 pp—
Mar 2022—+3.8 pp−7.1 pp−5.6 pp—
Jun 2022—−5.8 pp−2.0 pp−1.4 pp—
Sep 2022—−7.7 pp−3.2 pp−0.2 pp—
Dec 2022—−20.0 pp−1.2 pp−1.7 pp—
Mar 2023—−18.9 pp+4.0 pp−6.8 pp—
Jun 2023—−9.7 pp+4.5 pp−15.5 pp+1.3 pp
Sep 2023—−8.5 pp−5.1 pp−13.5 pp+20.4 pp
Dec 2023—+2.0 pp−4.0 pp−11.0 pp−2.0 pp
Mar 2024—+7.0 pp−3.0 pp−4.0 pp−6.0 pp
Jun 2024+5.6 pp+1.0 pp−5.0 pp0.0 pp+1.0 pp
Sep 2024+6.6 pp+6.0 pp+6.0 pp0.0 pp−1.0 pp
Dec 2024+2.5 pp+6.0 pp+9.0 pp+5.0 pp−4.0 pp
Mar 2025+10.5 pp+2.0 pp+9.0 pp+7.0 pp+3.0 pp
Jun 2025−1.0 pp+1.0 pp+8.0 pp+10.0 pp−8.0 pp
Sep 2025+3.0 pp+2.0 pp+11.0 pp+9.0 pp−7.0 pp
Dec 2025+5.0 pp+2.0 pp+13.0 pp+7.0 pp−5.0 pp
Mar 2026+4.0 pp−1.0 pp+14.0 pp+4.0 pp−8.0 pp
Jun 2026+1.0 pp+11.0 pp+9.0 pp+8.0 pp+2.0 pp
Sep 2026+6.0 pp+10.0 pp+9.0 pp+10.0 pp−2.0 pp

24 of 24 companies report OPM, 24 of 24 margin change.

OPM · highest

Margin change · fastest expanders

  1. 1Divis Laboratories LtdDIVISLAB+10.0 pp
  2. 2Laurus Labs LtdLAURUSLABS+10.0 pp
  3. 3Acutaas Chemicals LtdACUTAAS+9.0 pp
  4. 4Morepen Laboratories LtdMOREPENLAB+9.0 pp
  5. 5Hikal LtdHIKAL+8.1 pp

All-company data · latest reported quarter

Operating margin, every company
CompanyOPMMargin changeReported
Anthem Biosciences Ltd ANTHEM46%+6.0 ppSep 2026
Divis Laboratories Ltd DIVISLAB43%+10.0 ppSep 2026
Acutaas Chemicals Ltd ACUTAAS40%+9.0 ppSep 2026
Laurus Labs Ltd LAURUSLABS34%+10.0 ppSep 2026
Concord Biotech Ltd CONCORDBIO34%−2.0 ppSep 2026
OneSource Specialty Pharma Ltd ONESOURCE32%+4.0 ppSep 2026
Blue Jet Healthcare Ltd BLUEJET32%−1.0 ppSep 2026
Sai Life Sciences Ltd SAILIFE28%+1.0 ppSep 2026
Shilpa Medicare Ltd SHILPAMED27%−2.0 ppSep 2026
Gland Pharma Ltd GLAND26%+5.0 ppSep 2026
Neuland Laboratories Ltd NEULANDLAB22%−8.0 ppSep 2026
Granules India Ltd GRANULES22%+1.0 ppSep 2026
Supriya Lifescience Ltd SUPRIYA22%−14.0 ppSep 2026
SMS Pharmaceuticals Ltd SMSPHARMA21%+1.0 ppSep 2026
Syngene International Ltd SYNGENE18%−4.0 ppSep 2026
Solara Active Pharma Sciences Ltd SOLARA18%+7.0 ppSep 2026
Morepen Laboratories Ltd MOREPENLAB16%+9.0 ppSep 2026
IOL Chemicals & Pharmaceuticals Ltd IOLCP14%+4.0 ppSep 2026
Piramal Pharma Ltd PPLPHARMA13%+5.6 ppSep 2026
Windlas Biotech Ltd WINDLAS11%−2.0 ppSep 2026
Hikal Ltd HIKAL10%+8.1 ppSep 2026
Jubilant Pharmova Ltd JUBLPHARMA10%−7.0 ppSep 2026
Dishman Carbogen Amcis Ltd DCAL9.0%−14.0 ppSep 2026
Cohance Lifesciences Ltd COHANCE7.4%−14.4 ppSep 2026

What to watch

Watch whether the next two comparable periods confirm the current margin change rather than reversing it.

Which API and CDMO Pharma companies earn the most profit?

Divis Laboratories Ltd has the highest Net profit among the 24 Pharma - API & CRAMS companies compared here, at ₹3,363 crore. Laurus Labs Ltd is next at ₹1,332 crore. Shilpa Medicare Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Divis Laboratories Ltd earns the most, ₹3,363 crore of profit over the last 12 months, 152.5% above Laurus Labs Ltd. Shilpa Medicare Ltd shows at least 100% on the scoring scale (141.3% in full) growth from a profit base of ₹333 crore. A fast rate from a small base matters less than a large profit that keeps coming.

Divis Laboratories Ltd · ₹3,363 croreLeader
152.5% versus #2 · Laurus Labs LtdGap
7/8 recent comparable periodsPersistence
24/24 companies · 450 observationsCoverage

What this means: Divis Laboratories Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

  1. 1Divis Laboratories LtdDIVISLAB₹3,360 cr
  2. 2Laurus Labs LtdLAURUSLABS₹1,330 cr
  3. 3Gland Pharma LtdGLAND₹1,240 cr
  4. 4Granules India LtdGRANULES₹714 cr
  5. 5Anthem Biosciences LtdANTHEM₹614 cr

Profit growth · fastest growers

All-company data · latest reported quarter

Net profit, every company
CompanyNet profitProfit growthReported
Divis Laboratories Ltd DIVISLAB₹1,130 cr64%Sep 2026
Laurus Labs Ltd LAURUSLABS₹436 cr125%Sep 2026
Gland Pharma Ltd GLAND₹291 cr58%Sep 2026
Anthem Biosciences Ltd ANTHEM₹211 cr22%Sep 2026
Granules India Ltd GRANULES₹182 cr39%Sep 2026
Acutaas Chemicals Ltd ACUTAAS₹123 cr71%Sep 2026
Blue Jet Healthcare Ltd BLUEJET₹103 cr98%Sep 2026
Sai Life Sciences Ltd SAILIFE₹98 cr17%Sep 2026
Morepen Laboratories Ltd MOREPENLAB₹89 cr117%Sep 2026
Shilpa Medicare Ltd SHILPAMED₹79 cr80%Sep 2026
Concord Biotech Ltd CONCORDBIO₹70 cr11%Sep 2026
IOL Chemicals & Pharmaceuticals Ltd IOLCP₹65 cr117%Sep 2026
OneSource Specialty Pharma Ltd ONESOURCE₹57 cr470%Sep 2026
Neuland Laboratories Ltd NEULANDLAB₹52 cr−46%Sep 2026
SMS Pharmaceuticals Ltd SMSPHARMA₹40 cr60%Sep 2026
Syngene International Ltd SYNGENE₹32 cr−52%Sep 2026
Jubilant Pharmova Ltd JUBLPHARMA₹31 cr−74%Sep 2026
Supriya Lifescience Ltd SUPRIYA₹29 cr−42%Sep 2026
Solara Active Pharma Sciences Ltd SOLARA₹28 cr45%Sep 2026
Windlas Biotech Ltd WINDLAS₹18 cr0.0%Sep 2026
Piramal Pharma Ltd PPLPHARMA₹5 cr−106%Sep 2026
Cohance Lifesciences Ltd COHANCE₹2.3 cr−97%Sep 2026
Hikal Ltd HIKAL−₹6.1 cr−71%Sep 2026
Dishman Carbogen Amcis Ltd DCAL−₹67 cr−203%Sep 2026

What to watch

Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.

Which API and CDMO Pharma companies earn the best return on capital?

Acutaas Chemicals Ltd has the highest ROCE among the 24 Pharma - API & CRAMS companies compared here, at 31.6%. Anthem Biosciences Ltd is next at 30.4%. The same company also has the highest ROCE change, at +12 percentage points. 24 of 24 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Acutaas Chemicals Ltd leads ROCE at 31.6%, 1.2 percentage points above Anthem Biosciences Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

Acutaas Chemicals Ltd · 31.6%Leader
3.9% versus #2 · Anthem Biosciences LtdGap
Not enough historyPersistence
24/24 companies · 331 observationsCoverage

What this means: Acutaas Chemicals Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

Withheld from this chart: Acutaas Chemicals Ltd (ACUTAAS): its two data sources disagree by up to 22% on reported income across 15 comparable periods, so its derived ratios are withheld; Cohance Lifesciences Ltd (COHANCE): its two data sources disagree by up to 548% on reported income across 16 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.

ROCE · highest

ROCE change · fastest improvers

  1. 1Neuland Laboratories LtdNEULANDLAB+11.4 pp
  2. 2Laurus Labs LtdLAURUSLABS+8.4 pp
  3. 3Morepen Laboratories LtdMOREPENLAB+8.1 pp
  4. 4IOL Chemicals & Pharmaceuticals LtdIOLCP+5.5 pp

All-company data · latest reported quarter

Return on capital, every company
CompanyROCEROCE changeReported
Neuland Laboratories Ltd NEULANDLAB25%+11.4 ppSep 2026
Laurus Labs Ltd LAURUSLABS25%+8.4 ppSep 2026
Divis Laboratories Ltd DIVISLAB22%+4.3 ppSep 2026
Anthem Biosciences Ltd ANTHEM22%−1.9 ppSep 2026
Supriya Lifescience Ltd SUPRIYA18%−2.7 ppSep 2026
Sai Life Sciences Ltd SAILIFE17%+1.5 ppSep 2026
Concord Biotech Ltd CONCORDBIO16%−4.6 ppSep 2026
Morepen Laboratories Ltd MOREPENLAB15%+8.1 ppSep 2026
SMS Pharmaceuticals Ltd SMSPHARMA15%+0.9 ppSep 2026
Blue Jet Healthcare Ltd BLUEJET15%−18.0 ppSep 2026
Granules India Ltd GRANULES14%−2.3 ppSep 2026
IOL Chemicals & Pharmaceuticals Ltd IOLCP14%+5.5 ppSep 2026
Gland Pharma Ltd GLAND14%+4.1 ppSep 2026
Windlas Biotech Ltd WINDLAS14%−0.2 ppSep 2026
Shilpa Medicare Ltd SHILPAMED11%+2.0 ppSep 2026
Syngene International Ltd SYNGENE8.4%−3.1 ppSep 2026
Solara Active Pharma Sciences Ltd SOLARA7.7%+0.7 ppSep 2026
Jubilant Pharmova Ltd JUBLPHARMA6.5%−1.9 ppSep 2026
Hikal Ltd HIKAL6.4%+1.6 ppSep 2026
Piramal Pharma Ltd PPLPHARMA2.4%−0.3 ppSep 2026
Dishman Carbogen Amcis Ltd DCAL2.1%−2.0 ppSep 2026
OneSource Specialty Pharma Ltd ONESOURCE1.1%−0.9 ppSep 2026

What to watch

Watch whether the next two comparable periods confirm the current roce change rather than reversing it.

How are API and CDMO Pharma stocks valued against growth and quality?

Granules India Ltd has the lowest PEG among the 24 Pharma - API & CRAMS companies compared here, at 1.35×. Shilpa Medicare Ltd is next at 1.42×. Morepen Laboratories Ltd has the lowest P/E at 26.9×, so level and change sit with different companies. 12 of 24 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Granules India Ltd has the lowest comparable PEG at 1.35×, 4.9% below Shilpa Medicare Ltd. That would need today's multiple, the company's own history and steady growth to agree.

Granules India Ltd · 1.35×Leader
4.9% versus #2 · Shilpa Medicare LtdGap
0/8 recent comparable periodsPersistence
12/24 companies · 75 observationsCoverage

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG, by reported quarter

  • Granules India 0.9
  • Concord Biotech 3.4
  • Blue Jet Healthcare 1.4
  • Gland Pharma 0.9
PEG, by reported quarter
QuarterGranules IndiaConcord BiotechBlue Jet HealthcareGland Pharma
Dec 2021————
Mar 2022————
Jun 2022———1.7
Sep 2022———3.6
Dec 2022————
Mar 20230.7———
Jun 20230.5———
Sep 20233.5———
Dec 2023————
Mar 2024————
Jun 2024————
Sep 20242.0———
Dec 20241.21.85.7—
Mar 2025—7.61.4—
Jun 20251.42.1——
Sep 2025———6.3
Dec 2025—4.8—2.4
Mar 2026—3.4—1.5
Jun 20261.4———
Sep 20260.9——0.9

P/E, by reported quarter

  • Granules India 32.2×
  • Shilpa Medicare 70.8×
  • Concord Biotech 53.6×
  • Blue Jet Healthcare 42.0×
  • Gland Pharma 41.7×
P/E, by reported quarter
QuarterGranules IndiaShilpa MedicareConcord BiotechBlue Jet HealthcareGland Pharma
Dec 202117.5×147.8×——56.8×
Mar 202218.4×104.2×——44.3×
Jun 202215.4×63.6×——35.9×
Sep 202220.4×61.8×——31.6×
Dec 202215.9×113.0×——25.2×
Mar 202313.8×382.0×——21.1×
Jun 202313.9×396.9×——21.3×
Sep 202319.7×−260.9×47.8×—35.3×
Dec 202324.9×−3,941.6×64.8×40.0×43.2×
Mar 202426.4×125.6×52.2×41.6×43.8×
Jun 202429.5×180.6×54.5×41.0×38.9×
Sep 202427.4×192.1×68.4×54.4×40.7×
Dec 202429.2×130.9×69.1×54.8×43.1×
Mar 202524.6×76.7×53.9×65.4×37.2×
Jun 202525.2×93.3×51.3×49.2×42.0×
Sep 202526.2×57.6×46.1×31.2×41.9×
Dec 202529.3×40.0×39.5×26.1×34.5×
Mar 202628.5×38.1×29.9×20.3×32.9×
Jun 202631.4×47.9×37.9×36.9×36.6×
Sep 202632.2×70.8×53.6×42.0×41.7×

12 of 24 companies report PEG, 21 of 24 P/E.

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Valuation, every company
CompanyPEGP/EReported
Syngene International Ltd SYNGENE7.951.6×Sep 2026
Supriya Lifescience Ltd SUPRIYA3.439.8×Sep 2026
Hikal Ltd HIKAL3.463.3×Sep 2026
Concord Biotech Ltd CONCORDBIO3.453.6×Sep 2026
Windlas Biotech Ltd WINDLAS3.035.1×Sep 2026
Laurus Labs Ltd LAURUSLABS3.099.0×Sep 2026
Divis Laboratories Ltd DIVISLAB2.985.2×Sep 2026
Anthem Biosciences Ltd ANTHEM2.782.4×Sep 2026
Morepen Laboratories Ltd MOREPENLAB2.157.1×Sep 2026
SMS Pharmaceuticals Ltd SMSPHARMA1.642.8×Sep 2026
Blue Jet Healthcare Ltd BLUEJET1.442.0×Sep 2026
Neuland Laboratories Ltd NEULANDLAB1.155.6×Sep 2026
Granules India Ltd GRANULES0.932.2×Sep 2026
Gland Pharma Ltd GLAND0.941.7×Sep 2026
IOL Chemicals & Pharmaceuticals Ltd IOLCP0.732.9×Sep 2026
Sai Life Sciences Ltd SAILIFE—90.8×Sep 2026
Acutaas Chemicals Ltd ACUTAAS—69.4×Sep 2026
Piramal Pharma Ltd PPLPHARMA—−131.5×Sep 2026
Shilpa Medicare Ltd SHILPAMED—70.8×Sep 2026
OneSource Specialty Pharma Ltd ONESOURCE—−10,764.2×Sep 2026
Cohance Lifesciences Ltd COHANCE—163.2×Sep 2026
Jubilant Pharmova Ltd JUBLPHARMA—43.3×Sep 2026
Solara Active Pharma Sciences Ltd SOLARA—840.1×Sep 2026
Dishman Carbogen Amcis Ltd DCAL—145.4×Sep 2026

What to watch

Watch whether the next two comparable periods confirm the current p/e rather than reversing it.

Which stock lists do API and CDMO Pharma companies appear on?

Pharma - API & CRAMS companies show up on 7 of our India lists. The most are on the pharma stocks list (24 companies).

What can make this comparison misleading?

This Pharma - API & CRAMS comparison names 5 specific ways its own evidence can mislead, all listed below. All 24 companies here report on comparable dates, so no rank carries a stale marker. 2 have second-source figures left out because the two sources disagree. A high growth rate can still come from a very small starting figure.

Keep these limits visible

  • A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
  • The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • 2 companies are missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.

How was this comparison built?

This comparison is built from the reported filings of 24 Pharma - API & CRAMS companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.

FundamentalsThrough Sep 2026 · up to 20 quarters per company
Market dataThrough 13 November 2026 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and old evidence lowers confidence and pulls the 0 to 100 score toward the middle.
Source standing22 cross-checked · 0 unverified · 2 withheld, of 24 graded companies.

2 of 24 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Acutaas Chemicals Ltd (ACUTAAS): its two data sources disagree by up to 22% on reported income across 15 comparable periods, so its derived ratios are withheld; Cohance Lifesciences Ltd (COHANCE): its two data sources disagree by up to 548% on reported income across 16 comparable periods, so its derived ratios are withheld.

How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

What else do people ask about API and CDMO Pharma stocks?

These 24 answers restate the Pharma - API & CRAMS comparison above in question form. Every one is computed from the same 24 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.

Is the API and CDMO Pharma sector outperforming NIFTY 500?

Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over 52 weeks and by 11.8% over 13 weeks.

13 of 24 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 8 of the 18 with a long enough price history are ahead of the industry itself.

Which API and CDMO Pharma company is largest by revenue?

Divis Laboratories Ltd leads with revenue of ₹12,191 crore, based on 24 of 24 comparable companies through Sep 2026.

Which API and CDMO Pharma company is growing fastest?

Neuland Laboratories Ltd has the fastest current revenue growth at 50.5%, across 24 of 24 comparable companies.

Which API and CDMO Pharma company has the strongest 4-Factor Sector Score?

Laurus Labs Ltd ranks first at 74.4 out of 100, with 93% of the evidence available. The score ranks published data; it is not a recommendation.

Which API and CDMO Pharma company has the lowest comparable PEG?

Granules India Ltd has the lowest comparable PEG at 1.35, among 12 of 24 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this API and CDMO Pharma comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.

Is there a Nifty API and CDMO Pharma index?

The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.

Whether or not an official Nifty index covers Pharma - API & CRAMS, this page builds its own equal-weight basket of 24 listed Pharma - API & CRAMS companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.

Which are the best API and CDMO Pharma stocks in India?

Ranked by this page's four-factor score, Laurus Labs Ltd comes first among 24 listed Pharma - API & CRAMS companies, followed by Acutaas Chemicals Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.

How many API and CDMO Pharma stocks are listed in India?

This comparison covers 24 listed Pharma - API & CRAMS companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.

Which API and CDMO Pharma company is the biggest?

Divis Laboratories Ltd is the largest, with revenue of ₹12,191 crore over the last 12 months, ahead of Piramal Pharma Ltd at ₹9,779 crore. That covers 24 of 24 companies with comparable reporting through Sep 2026.

Which API and CDMO Pharma company has the best profit margins?

Anthem Biosciences Ltd has the highest operating margin at 45.6%, from 24 of 24 comparable companies. Divis Laboratories Ltd shows the biggest recent improvement, at +10 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.

Which API and CDMO Pharma company makes the most profit?

Divis Laboratories Ltd earns the most, at ₹3,363 crore of net profit over the last 12 months, from 24 of 24 comparable companies.

Shilpa Medicare Ltd has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.

Which API and CDMO Pharma company earns the highest return on capital?

Acutaas Chemicals Ltd leads on return on capital employed at 31.6%, across 24 of 24 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.

Which API and CDMO Pharma stock has the lowest PEG ratio?

On PEG (where a lower number means a lower price for what the company earns), Granules India Ltd has the lowest at 1.35×. Only 12 of 24 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a ranking of the whole industry.

A low multiple is a reason to look closer at the business, not a conclusion on its own.

Is the API and CDMO Pharma sector beating the market?

Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over the last 52 weeks and by 11.8% over 13 weeks, measured on an equal-weight index of its current members.

Inside the sector, 13 of the 24 companies we track are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which API and CDMO Pharma stock has the strongest price momentum?

Shilpa Medicare Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.

Which API and CDMO Pharma company has the highest 4-Factor score?

Laurus Labs Ltd scores 74.4 out of 100, with 93% of the evidence available, from 32.2 points on growth and earnings, 17.4 on capital efficiency, 7.1 on valuation and 17.7 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.

How many API and CDMO Pharma companies does this comparison cover, and over what period?

This comparison covers 24 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.

What is the total market cap of the API and CDMO Pharma sector?

The 24 Pharma - API & CRAMS companies on this page carry ₹8,12,768 crore of combined market value. Divis Laboratories Ltd is the largest at ₹2,93,316 crore, about 36% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.

What is the API and CDMO Pharma sector's P/E ratio?

The median price-to-earnings ratio across the 24 Pharma - API & CRAMS companies on this page is 56.5×, measured on the 21 that report a comparable figure.

A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 13 November 2026.

How is the API and CDMO Pharma sector performing?

13 of the 24 Pharma - API & CRAMS companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months).

The sector itself is 34.7% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.

Is this advice?

No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.

More lists

Every Sector Alpha list, grouped

Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.